Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01003912
Other study ID # Pro00010188
Secondary ID
Status Withdrawn
Phase Phase 1
First received October 20, 2009
Last updated June 27, 2017
Start date October 2009
Est. completion date March 2017

Study information

Verified date June 2017
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if it is safe to administer unrelated umbilical cord blood to pregnant women in their first trimester of pregnancy with a fetus that has a known diagnosis of certain lysosomal storage diseases. These diseases are known to cause severe and irreversible neurological disability in early infancy and which are lethal in childhood.


Description:

The purpose of this study is to determine the safety of first trimester fetal stem cell therapy using unrelated donor partially HLA-matched stem and progenitor cells derived from human umbilical cord blood for the treatment of selected lysosomal storage diseases that are known to cause severe and irreversible neurological disability in early infancy and which are lethal in childhood.

This study is designed as a prospective phase I open-label single center trial. It is designed to asses the safety and feasibility of administration of ALD-601 UCB cells to first trimester fetuses known to be affected with a lethal lysosomal storage disease. The sample size is 12 patients enrolled in cohorts of size 3. Safety measures will be monitored by an independent DSMC in each of the 4 cohorts prior to proceeding to the next cohort.

Biological parents being considered for therapy will have HLA testing, mutation analysis for disease status, and psychological counseling. Mothers will have ultrasounds for gestational age and chorion villus testing for mutation analysis for Krabbe, MLD, Tay Sachs, Sandhoff, or PMD (whichever appropriate). A crown-rump length will be determined the day before the scheduled transfer. The fetal weight will be calculated from formula: Y (kg) = (2.9026 x 10-1) (X 2.6528). The estimated fetal weight at that gestational age would be about 0.5 ounces or 14 grams. A suitably matched unrelated umbilical cord blood will be identified and the 20% portion will be manipulated for the isolation of ALD-601 cells. ALD-601 (ALDHbr) cells are isolated by high speed flow sorting on the FACSAria (BD Biosciences). Upon completion of the sort, ALD-601 UCB cells are counted, viability is determined, and the cellular composition of the sample is measured by analytical flow cytometry using fluorescence antibodies to lineage marker for T-cells, granulocytes, monocytes, and erythrocytes. The content of ALDHbr cells is also confirmed by analytical flow cytometry. A dose of 1 x 105 - 2 x 106 cells/kg of estimated fetal weight is suspended in 300 microliters of Cellgenix Stem Cell Medium (CellGenix, Inc.). Release criteria will allow a maximum of 5 x 104 T cells/kg. If the sorted sample contains greater than 5 x 104 T cells/kg it is re-sorted using the FACSAria and re-evaluated for cell number, viability, and cellular content. Sterility testing will include Bac-T/ALERT cultures, endotoxin measurement (LAL), and gram stain. After meeting criteria for product release, ALD-601 is transported at 2-8 degree C in a validated cooler to Duke and released to the Stem Cell Laboratory. Duke personnel will transport the cooler containing the ALD-601 product to the ultrasound suite, where the medical team will allow the ALD-601 to warm briefly to room temperature prior to injection. Under continuous ultrasound guidance, a 22-gauge X 5 inch procedure needle will be used to puncture the fetal peritoneal cavity. 100 microliters of sterile saline will be instilled to confirm intraperitoneal placement. The stem cell infusion will then be injected through the needle followed by the injection of 200 microliters (dead space of the needle: 60 microliters) to displace all cells from the dead space of the needle. An ultrasound will be performed 24 hours later to confirm fetal viability. A subsequent ultrasound will be undertaken at 18 weeks gestation to confirm viability, assess detailed fetal anatomy and adequate serial fetal growth.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 2017
Est. primary completion date March 2017
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Fetus with known enzymatic and, if possible, mutation diagnosis of selected lysosomal storage diseases, and history of enzymatic or mutation diagnosis of a previously affected family member.

- Krabbe disease

- Infantile metachromatic leukodystrophy disease (MLD)

- Tay Sachs or Sandhoff (GM2 gangliosidoses) disease

- Pelizaeus-Merzbacher disease (PMD).

- Both parents have the "at risk" genotype

- Both parents agree to psychological counseling prior to CVS

- Both parents agree to delivery of subject at Duke University

- Gestational age of < 9 weeks by sure menstrual dating or ultrasound of a natural pregnancy.

- Singleton fetus

- No evidence of abnormal nuchal thickening on preliminary ultrasound prior to chorion villus biopsy

Exclusion Criteria:

- Pregnancy by in vitro fertilization

- Evidence of a nuchal translucency of > 3.0 mm at the time of the ultrasound for the chorion villus biopsy.

- HIV, hepatitis C or hepatitis B positive maternal status

- Active infection in the mother at the time of scheduled CVS or cell injection as determined by clinical practice

Study Design


Intervention

Biological:
ALD-601
ALD-601 is manufactured by Aldagen from the 20% compartment of the selected umbilical cord blood unit within 24 hrs of planned injection. A dose of ALD-601 that delivers 1 x 105 - 2 x 106 cells/kg of estimated fetal weight at day - 1 is suspended in 300 microliters of dialysis media.

Locations

Country Name City State
United States Duke University Medical Center Durham North Carolina
United States Duke University Medical Center Pediatric Blood and Marrow Transplant Durham North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Joanne Kurtzberg, MD Aldagen

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine whether immune tolerance and donor cell engraftment can be achieved through first trimester injection of donor cells to fetus's diagnosed with lethal LSDs. after 3 patients
Primary Safety and feasibility of fetal intrap. after 3 patients
Secondary Donor chimerism for neonate at birth and 7 days post delivery. after 3 patients
Secondary Establishment of threshold enzyme levels in neonate at birth and 7 days post delivery. after 3 patients
Secondary Donor chimerism for mother post delivery and 1 year post date of birth. after 3 patients
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03548779 - North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 N/A
Completed NCT01049854 - CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant Phase 2
Completed NCT00001596 - Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome Phase 2
Completed NCT00744692 - Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders Phase 1
Completed NCT00692926 - Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells Phase 1
Recruiting NCT05818566 - Orphan Drugs for Inherited Metabolic Diseases
Completed NCT05330039 - Characterization of Intestinal Microbiota in Children With Inborn Errors of Metabolism (IEM)
Withdrawn NCT03866954 - Trial of Erythrocyte Encapsulated Thymidine Phosphorylase In Mitochondrial Neurogastrointestinal Encephalomyopathy Phase 2
Completed NCT03911089 - A Collection of Case Studies in Infants With UCD to Evaluate Infant Growth and the Safety of a New Medical Food for UCD N/A
Completed NCT03058848 - Evaluation of PKU Start N/A
Suspended NCT04399694 - Identification and Characterization of Novel Non-Coding Variants That Contribute to Genetic Disorders
Terminated NCT00654433 - ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases Phase 3
Completed NCT03168399 - Evaluation of PKU Explore N/A
Recruiting NCT00078078 - Clinical and Laboratory Study of Methylmalonic Acidemia
Completed NCT00328159 - Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids N/A
Completed NCT04309331 - Market Research - Acceptability Trial for a New PKU Amino Acid Based Protein Substitute N/A
Completed NCT04709965 - Evaluating Face-Recognition Technology in Syndrome Diagnosis N/A
Recruiting NCT06360913 - Blood Spot and Urine Metabolomic Screening Applied to Rare Diseases N/A
Completed NCT00309400 - The Early History of Universal Screening for Metabolic Disorders N/A
Completed NCT00004378 - Stem Cell Transplantation (SCT) for Genetic Diseases N/A